Comparing Sedation Regimens for Awake Fiberoptic Intubation  

作　　者：Gao-Pu Liu Fu-Shan Xue Chao Sun Gui-Zhen Yang 

机构地区：[1]Department of Anesthesiology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100144, China

出　　处：《Chinese Medical Journal》2016年第4期502-503,共2页中华医学杂志（英文版）

摘　　要：To the Editor： In a single-center, prospective, randomized double-blind clinical study comparing dexmedetomidine- midazolam and sufentanil-midazolam sedation regimens for awake fiberoptic intubation （AFOI） in 50 patients with difficult airways due to limited mouth opening, Li et al show that both dexmedetomidine and sufentanil are effective as an adjuvant for AFOI under airway topical anesthesia combined with midazolam sedation, but respiratory depression is a potential risk in the sufentanil-midazolam regimen. Given that AFOI has been established as the gold standard for difficult airway management, their findings have potentially clinical implications. In our view, however, there are several aspects of this study that need to be clarified and discussed.To the Editor： In a single-center, prospective, randomized double-blind clinical study comparing dexmedetomidine- midazolam and sufentanil-midazolam sedation regimens for awake fiberoptic intubation （AFOI） in 50 patients with difficult airways due to limited mouth opening, Li et al show that both dexmedetomidine and sufentanil are effective as an adjuvant for AFOI under airway topical anesthesia combined with midazolam sedation, but respiratory depression is a potential risk in the sufentanil-midazolam regimen. Given that AFOI has been established as the gold standard for difficult airway management, their findings have potentially clinical implications. In our view, however, there are several aspects of this study that need to be clarified and discussed.

分 类 号：TQ231.3[化学工程—有机化工] TQ520.5